{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-037619","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.125460+00:00","generated_at":"2026-06-04T09:27:00.849025+00:00","sec_items":["7.01","9.01","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gilead completes $4.3B acquisition of CymaBay; seladelpar added to liver pipeline","bullets":["Total equity value ~$4.3 billion; Gilead paid $32.50 per CymaBay share.","Tender offer resulted in 77.3% of shares tendered (93.7M shares); remaining shares converted at same price.","CymaBay becomes wholly owned subsidiary; CBAY to be delisted from Nasdaq on March 22, 2024.","Transaction expected to reduce Gilead's 2024 GAAP/non-GAAP EPS by $3.10-$3.20; including costs, $3.35-$3.45 relative to prior guidance.","Seladelpar (for primary biliary cholangitis) is key asset; safety/efficacy not yet established."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-037619","json":"https://secwatch.observer/filing/0001104659-24-037619.json","markdown":"https://secwatch.observer/filing/0001104659-24-037619.md","text":"https://secwatch.observer/filing/0001104659-24-037619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000110465924037619/0001104659-24-037619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000110465924037619/tm249475d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:27:00.849025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}